BRIEF-Polypid Receives PDUFA Fee Waiver From FDA For D-Plex₁₀₀’S New Drug Application

Reuters03-17

March 17 (Reuters) - PolyPid Ltd PYPD.O:

POLYPID RECEIVES PDUFA FEE WAIVER FROM FDA FOR D-PLEX₁₀₀’S NEW DRUG APPLICATION
POLYPID LTD - ON TRACK TO INITIATE NDA SUBMISSION FOR D-PLEX₁₀₀ BY END OF MARCH 2026

Source text: ID:nGNX7mm1yF

Further company coverage: PYPD.O

((Reuters.Briefs@thomsonreuters.com;))

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2620422899?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-17 20:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2620422899","market":"us","top_or_hot":-1,"title":"BRIEF-Polypid Receives PDUFA Fee Waiver From FDA For D-Plex₁₀₀’S New Drug Application","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Polypid Receives PDUFA Fee Waiver From FDA For D-Plex₁₀₀’S New Drug Application</title></head><body><p><span>March 17 (Reuters)</span><span> - </span>PolyPid Ltd <span>PYPD.O</span>:</p><ul><li><p>POLYPID RECEIVES PDUFA FEE WAIVER FROM FDA FOR D-PLEX₁₀₀’S NEW DRUG APPLICATION</p></li><li><p>POLYPID LTD - ON TRACK TO INITIATE NDA SUBMISSION FOR D-PLEX₁₀₀ BY END OF MARCH 2026</p></li></ul><p>Source text: <span>ID:nGNX7mm1yF</span></p><p>Further company coverage: <span>PYPD.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Polypid Receives PDUFA Fee Waiver From FDA For D-Plex₁₀₀’S New Drug Application</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Polypid Receives PDUFA Fee Waiver From FDA For D-Plex₁₀₀’S New Drug Application\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-17 20:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Polypid Receives PDUFA Fee Waiver From FDA For D-Plex₁₀₀’S New Drug Application</title></head><body><p><span>March 17 (Reuters)</span><span> - </span>PolyPid Ltd <span>PYPD.O</span>:</p><ul><li><p>POLYPID RECEIVES PDUFA FEE WAIVER FROM FDA FOR D-PLEX₁₀₀’S NEW DRUG APPLICATION</p></li><li><p>POLYPID LTD - ON TRACK TO INITIATE NDA SUBMISSION FOR D-PLEX₁₀₀ BY END OF MARCH 2026</p></li></ul><p>Source text: <span>ID:nGNX7mm1yF</span></p><p>Further company coverage: <span>PYPD.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nTUALMBKH:1","article_id":"2620422899","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2620422899","pubTimestamp":1773750711,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Polypid Receives PDUFA Fee WaiverFrom FDA For D-Plex’S New Drug ApplicationMarch 17 (Reuters) - PolyPid Ltd PYPD.O:POLYPID RECEIVES PDUFA FEE WAIVER FROM FDA FOR D-PLEX’S NEW DRUG APPLICATIONPOL","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","PYPD":"PolyPid Ltd."},"translate_title":"简介–Polypid获得FDA对D-Plex₁₀₀新药申请的PDUFA费用豁免","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PYPD":0.9},"content_text":"BRIEF-Polypid Receives PDUFA Fee Waiver From FDA For D-Plex₁₀₀’S New Drug ApplicationMarch 17 (Reuters) - PolyPid Ltd PYPD.O:POLYPID RECEIVES PDUFA FEE WAIVER FROM FDA FOR D-PLEX₁₀₀’S NEW DRUG APPLICATIONPOLYPID LTD - ON TRACK TO INITIATE NDA SUBMISSION FOR D-PLEX₁₀₀ BY END OF MARCH 2026Source text: ID:nGNX7mm1yFFurther company coverage: PYPD.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2620422899","isCrawlerRequest":true}